Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 3831-3840 Newer>

The Motley Fool October 7, 2004 Nathan Slaughter	Earnings News Welcome at Marriott The hotel operator reports an increase in both room rates and occupancy, with a 45% rise in Q3 earnings.
The Motley Fool October 7, 2004 Charly Travers	Santarus Takes on Big Pharma Can this small drug company compete with the industry's giants? Santarus bolstered its marketing efforts with the signing of a very beneficial partnership with Otsuka America Pharmaceutical.
The Motley Fool October 7, 2004 Seth Jayson	Painless? My Assets Another warning from dental tech firm Biolase Technology sends the stock down.
The Motley Fool October 7, 2004 Charly Travers	Amgen's Next Blockbuster An osteoporosis drug could give the company its next big winner. With a P/E back in the mid 20s, the company is valued such that Amgen shareholders should be rewarded in the future if products are successful.
The Motley Fool October 7, 2004 Lawrence Meyers	Quick Draw on Wynn Resorts Investors roll the dice on Steve Wynn's new resort, bidding the stock up though the place won't open until April.
The Motley Fool October 7, 2004 Seth Jayson	Clubbing Wet Seal A same-stores sales drop that's less than expected can't fix this retailer. It doesn't take a genius to figure out that a firm with $36 million in cash that's burning $20 million per quarter is going to run out of money pretty quickly.
The Motley Fool October 7, 2004 Bill Mann	Costco's Warehousing Money Operational efficiencies and a booming top line fuel Costco's amazing run. There should be good things to come for its shareholders.
The Motley Fool October 7, 2004 Tom Taulli	Steel Is Still a Steal After many decades, the steel industry has gotten some shine back and is, interestingly enough, looking like a growth sector again.
The Motley Fool October 7, 2004 Brian Gorman	Pfizer Will Weather the Storm The company will likely come out on top regardless of the outcome of the latest controversies. Pfizer remains a quality choice for long-term investors.
The Motley Fool October 7, 2004 Robert Brokamp	Financial Predators Does your financial advisor care more about your retirement, or his? Look for a broker with whom you can trust and has beat a relevant benchmark after fees and taxes over a three-year period.
<Older 3831-3840 Newer> Return to current articles.